《新股表现》快手(01024.HK)上市翌日倒跌逾3% 健倍苗苗(02161.HK)续升19%
公开发售一手中签率仅8%健倍苗苗(02161.HK)及公开发售一手中签率仅4%新股快手科技(01024.HK)继上周五首挂日升幅由最多近1.6倍至3.2元及2倍至345元,收窄至仅升80%及1.6倍後,今天股价个别发展,前者高开升至2.76元遇压,现造2.57元,续升19%,成交5,088万股,涉资1.31亿元;後者高开最多升3.3%至310元无以为继,掉头曾倒跌5.7%至283元新低,现造290.4元,倒跌3.2%,成交1,913万股,涉资56.86亿元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.